이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Aurora Spine 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

TSXV:ASG - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2024	16	-1	-1	0	N/A
12/31/2023	15	-2	-1	-1	N/A
9/30/2023	14	-2	-1	0	N/A
6/30/2023	14	-2	-1	0	N/A
3/31/2023	14	-2	-1	-1	N/A
12/31/2022	15	-2	-2	-2	N/A
9/30/2022	14	-2	-3	-1	N/A
6/30/2022	13	-2	-4	-3	N/A
3/31/2022	12	-2	-4	-3	N/A
12/31/2021	11	-2	-3	-2	N/A
9/30/2021	10	-1	-3	-2	N/A
6/30/2021	9	-1	-1	-1	N/A
3/31/2021	9	0	0	0	N/A
12/31/2020	9	0	0	0	N/A
9/30/2020	9	-1	0	1	N/A
6/30/2020	9	-2	0	0	N/A
3/31/2020	11	-2	-1	0	N/A
12/31/2019	11	-1	0	0	N/A
9/30/2019	11	-1	0	0	N/A
6/30/2019	11	0	0	0	N/A
3/31/2019	10	0	0	1	N/A
12/31/2018	9	0	0	0	N/A
9/30/2018	8	-1	0	0	N/A
6/30/2018	7	-1	-1	-1	N/A
3/31/2018	6	-2	-1	-1	N/A
12/31/2017	6	-2	N/A	-1	N/A
9/30/2017	6	-2	N/A	-1	N/A
6/30/2017	6	-2	N/A	-1	N/A
3/31/2017	7	-2	N/A	-2	N/A
12/31/2016	7	-2	N/A	-2	N/A
9/30/2016	7	-2	N/A	-2	N/A
6/30/2016	6	-2	N/A	-2	N/A
3/31/2016	5	-2	N/A	-2	N/A
12/31/2015	5	-3	N/A	-3	N/A
9/30/2015	5	-5	N/A	-4	N/A
6/30/2015	4	-6	N/A	-6	N/A
3/31/2015	4	-8	N/A	-7	N/A
12/31/2014	3	-8	N/A	-7	N/A
9/30/2014	1	-6	N/A	-7	N/A
6/30/2014	1	-5	N/A	-5	N/A
3/31/2014	0	-4	N/A	-4	N/A
12/31/2013	0	-3	N/A	-3	N/A
9/30/2013	0	-3	N/A	-3	N/A

애널리스트 미래 성장 예측

수입 대 저축률: ASG 의 예상 수익 증가율이 절약률( 2.1% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: ASG 의 수익이 Canadian 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: ASG 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: ASG 의 수익이 Canadian 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: ASG 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: ASG 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Aurora Spine 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Aurora Spine Corporation Provides Revenue Guidance for Fourth Quarter and Full Year 2021

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Recent updates

We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package

Is Aurora Spine (CVE:ASG) A Risky Investment?

Full year 2023 earnings released: US$0.02 loss per share (vs US$0.022 loss in FY 2022)

Aurora Spine Corporation to Report Q1, 2024 Results on May 13, 2024

Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024

New minor risk - Insider selling

Independent Director recently sold CA$135k worth of stock

There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding

New minor risk - Share price stability

Aurora Spine Corporation to Showcase Sacroiliac Joint (Si Joint) Fusion Products At North American Neuromodulation Society Annual Meeting

Aurora Spine Corporation Announces Newly Published Paper on First 6-Month Clinical Evaluation of its ZIP™? Fusion Implant

Third quarter 2023 earnings released: US$0.004 loss per share (vs US$0.002 loss in 3Q 2022)

Independent Director recently bought CA$105k worth of stock

Aurora Spine Corporation announced that it has received CAD 1.933782 million in funding

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Corporation Announces Full Release of its SiLO TFX™? MIS Sacroiliac Joint Fixation System

Second quarter 2023 earnings released: US$0.01 loss per share (vs US$0.002 loss in 2Q 2022)

Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S

Aurora Spine Corporation Announces Initial Patient Enrolled for DEXA-CTM Multicenter Study

Aurora Spine Corporation to Report Q1, 2023 Results on May 24, 2023

Aurora Spine Corporation, Annual General Meeting, Jun 28, 2023

Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt

Full year 2022 earnings released: US$0.02 loss per share (vs US$0.04 loss in FY 2021)

Independent Chairman exercised options to buy CA$355k worth of stock.

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Third quarter 2022 earnings released: US$0.002 loss per share (vs US$0.007 loss in 3Q 2021)

Aurora Spine Corporation to Report Q3, 2022 Results on Nov 21, 2022

Insufficient new directors

Aurora Spine Corporation Announces Positive Interim Results from Clinical Study Using Zip(TM) MIS Interspinous Fusion System

Aurora Spine Corporation Announces FDA 510(K) Clearance for Its Silo TFX MIS Sacroiliac Joint Fixation System

Second quarter 2022 earnings released: US$0.002 loss per share (vs US$0.013 loss in 2Q 2021)

Aurora Spine Corporation to Report Q2, 2022 Results on Aug 29, 2022

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Announces New FDA Indication Clearance of Lumbar Spinal Stenosis for Its ZIP™ Series of MIS Implants

Aurora Spine Corporation Receives FDA 510(K) Clearance for Its Dexa Solo-LTM Spinal Fusion System

Aurora Spine Corporation to Report Q1, 2022 Results on May 23, 2022

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Full year 2021 earnings released: US$0.04 loss per share (vs US$0.004 loss in FY 2020)

Insufficient new directors

Aurora Spine Corporation Announces Initial Implantation of the First Bone Density Matched DEXA-C Cervical Interbody Fusion Device

Aurora Spine Corporation Provides Revenue Guidance for Fourth Quarter and Full Year 2021

Aurora Spine Corporation Receives Notice of Allowance for Patent for Spinal Implant for Motion Preservation or Fusion

Aurora Spine Corporation Completes First Anterior Cervical Discectomy and Fusion Procedures with its Proprietary APOLLOTM Anterior Cervical Plate

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Aurora Spine Corporation Announces Newly Published Paper on Need for A Bone Mineral Density-Matched Interbody Cage

Third quarter 2021 earnings released: US$0.02 loss per share (vs US$0.006 profit in 3Q 2020)

Aurora Spine Corporation Will Showcase Its New FDA-Cleared DEXA-C Anterior Fusion Cages At the North American Spine Society Annual Meeting

Aurora Spine Corporation announced that it has received CAD 6.508139 million in funding

Second quarter 2021 earnings released: US$0.01 loss per share (vs US$0.001 profit in 2Q 2020)

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Aurora Spine Corporation Announces First Patients in Multicenter Study of ZIP® Interspinous Fixation Device

Aurora Spine Corporation Announces FDA 510(K) Clearance for DEXA-C Cervical Interbody System

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

First quarter 2021 earnings released: US$0.01 loss per share (vs US$0.011 loss in 1Q 2020)

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Aurora Spine Corporation Receives Irb Approval to Commence Registration for Multicenter Study of Its Silo™ Device for Si Joint Pain

Full year 2020 earnings released

Aurora Spine Corporation Announces Launch of its SiLOTM Posterior SI Joint Fusion System

A Look At The Intrinsic Value Of Aurora Spine Corporation (CVE:ASG)

New 90-day high: CA$0.53

Aurora Spine Corporation(TSXV:ASG) dropped from S&P/TSX Venture Composite Index

New 90-day high: CA$0.44

New 90-day high: CA$0.38

Aurora Spine Plans A Major Multicenter Study of Its ZIPTM Interspinous Fixation Device for Relief of Back Pain

New 90-day high: CA$0.36

Third quarter 2020 earnings released: EPS US$0.01

Is Aurora Spine (CVE:ASG) A Risky Investment?

Aurora Spine Corporation Announces Commercial Launch of The SOLO™ System

New 90-day high: CA$0.31

First half earnings released

수익 및 매출 성장 예측

애널리스트 미래 성장 예측